Weil is serving as antitrust counsel to Forest Laboratories, a leading, fully integrated, specialty pharmaceutical company largely focused on the United States market, in its acquisition by Actavis, a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The transaction is valued at approximately $25 billion and if successfully completed, the transaction will combine two of the world’s fastest-growing specialty pharmaceutical companies.
The Weil Antitrust Team includes partners Steven Newborn (Washington, DC), Ann Malester (Washington, DC), Steven Bernstein (Washington, DC) and Douglas Nave (London); counsel John Sipple (Washington, DC); and associates Dan Antalics (Washington, DC), Jane Cooper (New York), Albert Cahn (New York), and Nafees Saeed (London).
